Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

OncLive

The FDA has approved the imaging product TLX591-CDx as a radioactive diagnostic agent for PET of prostate-specific membrane antigen positive lesions in patients with prostate cancer who have suspected metastasis who are candidates for initial definitive therapy, and in those with suspected recurrence based on elevated serum prostate-specific antigen level.

  • 123456 Profile photo of Madelyn

    PSMA-PET imaging will likely continue to become more widely available